HEALTHCARE

The company says it is making structural adjustments, mainly in the development department.

The company's revenue is growing, but it is yet to post a profit. CEO Maurice Ferré: The market no longer tolerates losses.

Haifa University researchers have found that synchronization between organs declines with age, opening up new possibilities for diagnostics, and perhaps even intervention.

The company's transcatheter approach introduces a new minimally invasive therapeutic option for heart failure patients who have limited effective treatments today.

The Israeli company is developing AI-based personalized medicines in collaboration with Oracle.

Challenges will be announced twice a year for startups to offer technological solutions for Teva's entire drug development chain.

Besides its regular donors, the institute is asking the general public to help restore facilities hit by an Iranian missile. Ben Gurion University has embarked on a similar campaign.

The company has developed the ORYOM robotic surgery platform for cataract and other eye diseases.

The company has emerged from stealth and announced that it has raised $3.6 million in a pre-seed financing round.

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery.

Investors highlighted challenges and strategic models in life sciences funding, in a forum co-hosted by Lipa Meir & Co.

The company sees revenue from its leading products doubling to $5 billion by 2030.

The Israeli pharmaceutical company's debt at the end of the first quarter of 2025 was $16.7 billion, after the company repaid $1.4 billion in debt during the quarter.

Over the past 15 years, Israeli startups have been applying Big Data to cure the US healthcare system’s ills. How do they do it, and can they maintain their advantage?

Somite AI is building DeltaStem, a platform and foundation model designed to revolutionize the production of human cells.

Pharma companies everywhere have been hit by the US president's announcement that he will cut prices of drugs to their lowest prices globally.

Market sources believe that the rate of layoffs in Israel will be similar to the general rate worldwide.

The Israeli pharmaceutical company's 3,000 layoffs will help the company achieve its targets for growth and higher profitability.

The Israeli pharmaceutical company unexpectedly announced the layoffs after publishing its first quarter results.

The donation, from Blackstone president Jon Gray and his wife Mindy, will enable the university's Faculty of Medical and Health Sciences to expand both in medical studies and research.

The FDA has ruled that SELARSDI, which Teva has launched with Alvotech, is interchangeable with Stelara for treating adult and pediatric psoriatic arthritis and plaque psoriasis, as well as Crohn's disease, and ulcerative colitis.

In the commercialization deal, Spanish pharmaceutical company Ferrer will receive the rights to market the drug in Europe, while the US market will remain in Prilenia's hands.

The UK pharmaceutical giant is teaming with Tel Aviv University and the Meuhedet and Leumit health funds on the project.

Healthee’s benefits and care navigation platform empowers employees and employers to make the most of their health benefits.

Personal experience motivated Roy Goldenberg to become Israel director of TOM Tikkun Olam Makers. "TOM will be one of the biggest organizations to come out of Israel," he says.

The death of a cancer patient spurred Dr. Adi Zoref-Lorenz into developing the OHI index, which allows the diagnosis of the HLH side effect from cancer immunotherapy, based on two blood tests.

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Insightec COO and general manager Eyal Zadicario tells "Globes" about himself and the Israeli ultrasound company's long battle to change the medical world.

Navina equips clinicians and care teams with real-time, data-driven insights that improve the quality of care and financial outcomes.

"We know nothing about the female reproductive system," says Dr. Ola Gutzeit of Rambam Hospital. She seeks to change that, and hence change IVF for the better.